Departments of Orthopedics, Division of Sports Medicine.
Harvard Medical School, Boston, Massachusetts, USA.
J Ultrasound Med. 2019 Jun;38(6):1527-1536. doi: 10.1002/jum.14841. Epub 2018 Oct 31.
Treatment for iliopsoas tendinopathy includes ultrasound (US)-guided iliopsoas peritendinous corticosteroid injection. Evidence is lacking regarding US-guided iliopsoas injection efficacy in patients with iliopsoas tendinopathy and intra-articular (IA) hip abnormalities. The purpose of this study was to examine the efficacy of US-guided iliopsoas corticosteroid injection for iliopsoas tendinopathy in patients with and without IA hip abnormalities.
This work was a prospective study evaluating patients aged 12 to 50 years with iliopsoas tendinopathy. Participants completed a Hip Disability and Osteoarthritis Outcome Score (HOOS) questionnaire before and 6 weeks after injection. The main outcome measure was the change in HOOS subcategory scores. Independent variables included time and hip status. Normal hips were compared to abnormal hips with IA abnormalities. A 2-way repeated measures analysis of covariance with effect size (η ) was used to determine injection effects on HOOS scores before and 6 weeks after injection.
A total of 178 patients (154 female and 24 male) were analyzed. Time effects were found for both normal and abnormal hips in all HOOS subcategories: symptoms (P = .041; η = 0.050), pain (P = .001; η = 0.184), activities of daily living (P = .011; η = 0.076), function in sports and recreation (P = .001; η = 0.151), and quality of life (QOL; P = .001; η = 0.193). Significant differences between normal versus abnormal hips were found in the sports and recreation (P = .032; η = 0.056) and QOL scores (P = .001; η = 0.135).
In patients with iliopsoas tendinopathy, US-guided iliopsoas corticosteroid injection improved outcomes regardless of coexisting IA hip abnormalities. Patients without IA hip abnormalities showed greater improvement in sports and recreation and QOL scores compared to patients with IA hip abnormalities. Ultrasound-guided iliopsoas injection for iliopsoas tendinopathy may advance short-term care and help continue with nonsurgical treatment regimens.
治疗髂腰肌肌腱病包括超声(US)引导的髂腰肌肌腱周围皮质类固醇注射。对于患有髂腰肌肌腱病和髋关节腔内(IA)异常的患者,US 引导的髂腰肌注射的疗效缺乏证据。本研究的目的是检查 US 引导的髂腰肌皮质类固醇注射治疗髂腰肌肌腱病的疗效,无论患者是否存在 IA 髋关节异常。
这是一项前瞻性研究,评估了 12 至 50 岁患有髂腰肌肌腱病的患者。参与者在注射前和注射后 6 周完成髋关节残疾和骨关节炎结果评分(HOOS)问卷。主要观察指标是 HOOS 亚类评分的变化。自变量包括时间和髋关节状态。正常髋关节与伴有 IA 异常的异常髋关节进行比较。采用双向重复测量方差分析和效应量(η)来确定注射对注射前和注射后 6 周 HOOS 评分的影响。
共分析了 178 名患者(154 名女性和 24 名男性)。正常和异常髋关节在所有 HOOS 亚类中均发现时间效应:症状(P = .041;η = 0.050)、疼痛(P = .001;η = 0.184)、日常生活活动(P = .011;η = 0.076)、运动和娱乐活动中的功能(P = .001;η = 0.151)和生活质量(QOL;P = .001;η = 0.193)。正常髋关节与异常髋关节在运动和娱乐(P = .032;η = 0.056)和 QOL 评分(P = .001;η = 0.135)方面存在显著差异。
对于患有髂腰肌肌腱病的患者,US 引导的髂腰肌皮质类固醇注射可改善预后,无论是否存在伴发的 IA 髋关节异常。与 IA 髋关节异常的患者相比,无 IA 髋关节异常的患者在运动和娱乐以及 QOL 评分方面的改善更为明显。US 引导的髂腰肌注射治疗髂腰肌肌腱病可能会促进短期治疗,并有助于继续非手术治疗方案。